Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, has reinforced its early stage topical and semi-solids capability by investing in a Becomix homogeniser mixer
The company said that the installation and validation of the new equipment extends its ability to manufacture creams, ointments and semi-solids as well as enabling it to efficiently deal with more complex formulations.
Used primarily for the production of topical drug products, the Becomix RW30 model homogeniser gives the contract development and manufacturing organisation (CDMO) the scalability to now supply products for Phase III studies, according to Juniper Pharma Services.
Claire Madden-Smith, SVP at Juniper Pharma Services, said: “This addition to our capabilities enables us to develop topical products on a larger scale and to cater for our clients’ supply needs from first-in-man studies up to and including Phase III, with a commercially replicable process in place.
“We are no stranger to aiding clients with challenging formulations and so the installation of Becomix simply bolsters our ability to support drug development companies that are developing creams, ointments, and semi-solid products, both simple and complex.”
With an integrated electronic batch report system in place, the Becomix is designed to reduce operator input and automate the homogenisation process.
This is the latest major equipment initiative by Juniper Pharma Services’ CDMO, which recently announced a substantial investment in its spray drying capabilities.